For direct compression of liposomal vitamin C API, the phospholipid-to-ascorbic acid ratio controls both powder rheology and the upper limit of tablet press force. Formulation work on force-feeder-equipped 27-station rotary presses has shown that total liposomal powder inclusion levels of 30–55 wt% with a liposomal ascorbic acid load of 30–50% w/w deliver 250–1000 mg elemental ascorbic acid per unit, while higher phospholipid content above 25 wt% of the total tablet mass increases sticking to polished tungsten carbide punches unless the granulation is pre-dried to moisture below 3.0% by Karl Fischer titration and the compression room is held at 20–25 °C and 40–50% RH. In-process testing follows USP <905> for weight variation and content uniformity, with dissolution assessed by USP <711> apparatus 2 at 50 rpm in 900 mL phosphate buffer pH 6.8; release from non-enteric liposomal tablets commonly requires Q=75% at 45 min, but published data for this specific liposomal ascorbic acid configuration is limited and should be established per product. The downstream process includes sifting through a 0.85 mm mesh, low-shear blending in a V-blender with 1.0–2.0 wt% magnesium stearate added as a final extragranular lubricant, compression at 8–18 kN and turret speeds of 20–45 rpm, and aqueous film coating with hydroxypropyl methylcellulose to a 2.5–3.5% weight gain. Terminal product types include 500 mg and 1000 mg film-coated tablets, bilayered antioxidant tablets combining liposomal vitamin C with zinc bisglycinate, and chewable tablets when the liposomal powder is co-processed with mannitol and crospovidone to offset low plasticity.

Independent of the primary addition ratio, tablets containing more than 25 wt% phospholipid display a non-linear reduction in tensile strength above 15 kN compression force due to lipid extrusion into interparticulate void spaces; on Korsch XL 400-class presses, this is observed as edge cracking and punch filming within the first 2 h of a continuous run. Pre-drying at 40 °C for 6–8 h in a tray dryer followed by active dehumidification at ≤40% RH prevents moisture-mediated adhesion, while tablet hardness is maintained at 70–120 N for standard concave punches and friability remains below 1.0% when tested by USP <1216>.

Why Does Powder Bridging and Plug Fracture Occur During Automatic Capsule Filling of Liposomal Ascorbic Acid?

In hard gelatin and HPMC capsule filling on intermittent-motion machines, the low bulk density of liposomal vitamin C—commonly 0.25–0.45 g/mL—combined with phospholipid surface adhesion is the primary cause of dosator plug fracture and tamping-pin sticking. A typical loading range is 40–70 wt% of the fill mass when the liposomal powder contains 30–50% w/w ascorbic acid and is pre-granulated with microcrystalline cellulose; below 0.30 g/mL bulk density, the fraction is reduced to 35–50 wt% to maintain fill weight variation at ≤5% RSD under USP <905> and Ph. Eur. 2.9.40. The capsule process requires drying to 3.5% water content, sifting through 0.71 mm mesh, and blending with 0.5–1.5 wt% colloidal silicon dioxide and 1–2 wt% magnesium stearate; tamping pin compression force should be kept below 200 N per pin on a Bosch GKF 1500-class dosator machine, with pin height adjusted to produce a plug length of 60–80% of the body length. In-process control includes periodic fill weight checks every 15 min and disintegration testing by USP <701> for hard gelatin capsules, while dissolution is run by USP <711> apparatus 1 at 100 rpm in 900 mL phosphate buffer pH 6.8 for HPMC capsules. Finished product presentations include 500 mg and 750 mg liposomal vitamin C hard-shell capsules, lipid-matrix capsule blends with citrus bioflavonoids, and HPMC two-piece capsules for vegetarian-label products where the fill is composed of liposomal pellets and riboflavin-stained placebo pellets to visually distinguish dual-release populations.

Stick-Pack Reconstitutable Granules: Fluid-Bed Spray Granulation of Phospholipid-Encapsulated Ascorbic Acid

A key processing constraint in low-pH reconstitutable granules is that liposomal vitamin C undergoes bilayer hydrolysis when exposed to free water at pH below 3.5; therefore, granulation must use a hydroalcoholic or ethanol-based binder rather than aqueous solutions. The API is incorporated at 35–60 wt% of dry granule mass with 5–10 wt% HPMC E5 or PVP K30 binder and 10–20 wt% mannitol or maltodextrin to maintain rapid dispersion. Fluid-bed top-spray granulation is operated on a Glatt GPCG 3.1-class unit with inlet air at 50–65 °C, product temperature at 28–35 °C, spray rate 5–15 g/min, and atomizing air pressure 1.0–1.5 bar; the granules are dried to 2.5–3.5% loss-on-drying and sieved to 150–850 µm to match stick-pack filling requirements. Regulatory release follows USP <711> dissolution applied to the reconstituted suspension, USP <731> loss on drying, and USP <905> for content uniformity of filled sachet weight; if the product is marketed in the EU, Ph. Eur. 2.9.5 for viscosity may be applied to the reconstituted liquid. Finished formats derived from this granulation line include single-dose 10 mL stick packs containing 1000 mg liposomal vitamin C, low-sugar oral powder for solution, and pediatric sachets where the fill is blended with xylitol and silica to control electrostatic attraction during high-speed vertical form-fill-seal packing.

Freeze-drying of parenteral-grade liposomal ascorbic acid is constrained by the glass transition of the phospholipid bilayer and the crystalline behavior of ascorbic acid in the frozen matrix. Published data for this specific liposomal ascorbic acid configuration is limited, but formulation studies on related phosphatidylcholine liposomes indicate a starting formulation of 10–30 mg/mL ascorbic acid equivalent and 20–50 mg/mL total phospholipid with 5–10% w/v sucrose or trehalose as lyoprotectant; without the disaccharide, a collapse temperature below -30 °C produces cracked cakes and subvisible phospholipid aggregates upon reconstitution. The lyophilization cycle uses controlled nucleation, annealing at -10 °C for 2–4 h, primary drying at -30 to -20 °C with chamber pressure 50–100 mTorr for 48–72 h, and secondary drying at 20–25 °C for 6–12 h to reach residual water below 2.0% by USP <921>. Sterility assurance is provided by aseptic filtration with a 0.22 µm PVDF membrane and filling in an ISO 14644-1 Class 5 environment under EU GMP Annex 1; endotoxin limits are set per USP <85> and particulate matter per USP <788>. Lyophilized presentations produced under this cycle include 5 mL and 10 mL lyophilized vials reconstituted with sterile water for injection to 50–100 mg/mL ascorbic acid equivalent, and freeze-dried combination vials with sodium bicarbonate for pH adjustment during slow intravenous infusion.

Stopping or shortening primary drying produces large collapsed regions at the vial edge, whereas over-drying below 2.0% residual water without adequate trehalose increases lyso-phosphatidylcholine hydrolysis and raises subvisible particulate counts. On a production-scale shelf freeze dryer with controlled nucleation, thermocouple and Pirani pressure comparisons are used to determine endpoint; vials are stoppered under vacuum or nitrogen at 50–80 kPa and then sealed with flip-off caps. Aseptic processing is subject to 21 CFR 211.67 equipment cleaning and 21 CFR 211.94 container closure integrity, with media fills requiring no growth in 3,000 units as per EU GMP Annex 1 guidance.

Parenteral Liquid Injection Line Filtration Limits and Subvisible Particle Controls

When a liquid parenteral dosage form is selected, the liposomal particle size distribution before terminal filtration dictates whether the batch can be sterile-filtered or must be extemporaneously prepared at hospital pharmacy level. Injection formulations are prepared with 5–20 mg/mL ascorbic acid equivalent and 10–30 mg/mL high-purity phosphatidylcholine at pH 5.5–6.5, using histidine or citrate buffer at 10–25 mM to avoid osmotic stress; addition ratios above 20 mg/mL ascorbic acid can generate hypoosmotic bilayer rupture if the phospholipid concentration is not raised in parallel. The production process requires high-shear homogenization at 10,000–15,000 rpm for 30–60 min, size reduction through polycarbonate track-etched membranes at 0.4 µm and 0.22 µm, and final sterilizing-grade filtration through a 0.22 µm PVDF filter with pre-use and post-use integrity testing per 21 CFR 211.72 and release per 21 CFR 211.165. Release testing includes USP <729> for liposomal drug products, USP <788> for subvisible particulate matter, USP <790> for visible particulates, USP <85> for bacterial endotoxins, and USP <791> for pH; sterility testing follows USP <71>. Marketed configurations stemming from this process include 5 mL and 10 mL amber ampoules, ready-to-use vials for slow intravenous injection after dilution in 0.9% sodium chloride, and intramuscular injection forms where the phospholipid matrix is adjusted to reduce local irritation at the injection site.

When Delayed-Release Multiparticulate Coating Is Required for Oral Liposomal Ascorbic Acid

Delayed-release multiparticulate coating is evaluated only when gastric degradation of the phospholipid bilayer would compromise the intended absorption window. The core pellet is prepared by layering liposomal vitamin C onto sugar spheres using a Wurster bottom-spray insert; the drug-layering dispersion contains 25–50 wt% liposomal powder based on dry solids, with 5–10 wt% HPMC E5 as binder and talc as anti-tack agent. A coating weight gain of 10–15% w/w with Eudragit L30 D-55 dispersion is applied at product temperature 30–38 °C, inlet air 40–50 °C, and atomizing air 0.8–1.2 bar; the coated pellets are cured at 40 °C for 2 h and then filled into hard capsules at 40–60% of the fill weight to achieve target ascorbic acid dose. Compliance testing references USP <711> with sequential dissolution media: 2 h in 0.1 M HCl followed by phosphate buffer pH 6.8, with a lag-time specification of ≤10% release in acid after 2 h and ≥75% release within 60 min in buffer. The coating operation yields 500 mg gastro-resistant capsules, sprinkle multiparticulate sachets, and enteric-coated tablets if the pellets are compressed with placebo granules and the tablet hardness is kept below 120 N to preserve pellet integrity.

Coating defects such as sticking on the Wurster bed arise when the product temperature exceeds 38 °C or the Eudragit dispersion is sprayed faster than 5–10 g/min, producing agglomerates with incomplete gastric resistance. A dispersion solids content of 20–25% w/w and a plasticizer level of 10–20% by polymer weight are required to prevent film cracking on compaction; triethyl citrate is preferred over dibutyl phthalate where potential exposure limits apply. Release testing applies USP <711> with sequential acid and buffer stages; the acid-resistance specification is normally ≤10% release after 2 h in 0.1 M HCl, and buffer-stage release is ≥75% within 60 min at pH 6.8 for products intended as gastro-resistant oral dosage forms.